Britain and America have agreed to a significant bilateral deal that will maintain zero tariffs on UK drug exports entering the American market.
Agreement Details of the Accord
In exchange for the tariff guarantee, the UK has pledged to increase expenditure on medicines through the NHS. This pledge guarantees that tariffs on these crucial goods will stay at nothing for a period of three years.
This deal comes after earlier warnings to significantly raise import taxes on patented pharmaceutical products, with increases discussed up to one hundred percent.
"This agreement between the United Kingdom strengthens the international landscape for new treatments and establishes much-needed balance to transatlantic pharmaceutical trade," a statement noted.
Trade Impact
Drugs are one of the the United Kingdom's largest goods shipped to the US, which is by far the biggest buyer for major British pharmaceutical firms.
Export figures show that in the year leading up to September, the UK sold drugs totaling billions to the US. This value represented a significant portion of British export trade in that timeframe.
"This agreement protects jobs, stimulates capital expenditure and facilitates the UK to establish itself as a global hub for life sciences," the Business and Trade Secretary commented.
Specific British Pledges
The pact involves several key changes from the United Kingdom:
- Revised Affordability Limit: The UK will raise the price threshold at which it judges new therapies to be too expensive by 25%.
- Higher Drug Budget: There is a aim to raise total public funding on medicines from 0.3 percent of the national economy to 0.6 percent over the coming ten years.
- Payback Limit: The percentage drug companies must refund to the NHS to prevent overspending will be capped at 15%. Previously, refunds exceeded twenty percent.
Industry Background
This agreement follows a long-running dispute between the drug companies and the ministers over medicine costs and approval rates.
This friction were intensified by claims that American customers were paying significantly more for the same drugs than consumers in the Britain and the EU.
Over the last 18 months, several large pharmaceutical investments in the UK have been paused or abandoned, while multi-billion-dollar expansions have been pledged toward projects in the United States.
The Science Minister acknowledged that the NHS needed to invest a greater share on treatments, noting that its spending on drugs had shrunk as a proportion of its resources over the last ten years.
